Objective:To investigate the cognitive status of fatigue among patients with coronary heart disease (CHD) in the community and analyze its influencing factors.Methods:From May to July 2020, a total of 250 patients with CHD in the community were selected as the research objects by multi-stage sampling method. The general information questionnaire and Fatigue Cognition Questionnaire for Patients with CHD were used for investigation. Multiple linear regression analysis was used to analyze the influencing factors. A total of 250 questionnaires were distributed and 245 were effectively recovered.Results:The total score of fatigue cognition of 245 patients with CHD in the community was 6 (4, 7) . Univariate analysis showed that there were statistically significant differences in the total scores of fatigue cognition among community CHD patients with different education level, duration of disease, grading of cardiac function, whether pay attention to fatigue knowledge, number of combined chronic diseases and treatment methods ( P<0.05) . Multiple linear regression analysis showed that education level, duration of disease, whether pay attention to fatigue knowledge, number of combined chronic diseases and treatment methods were the main influencing factors on fatigue cognition of CHD patients in the community ( P<0.05) . Conclusions:The cognition of patients with CHD in the community on fatigue needs to be improved, and community medical workers should take corresponding measures to increase the attention and active response of patients with CHD to fatigue.

Antimicrobial resistance is on the rise while the number of antibiotics being brought to market continues to drop. Drug-resistant genes and drug-resistant bacteria infection have seriously threatened human health. Therefore, antimicrobial resistance presents an ongoing challenge that requires multifaceted approaches including: biomedical innovation; improved surveillance of antibiotic consumption and antimicrobial resistance generated rates; prevention of health-care-associated infections and transmission of multidrug-resistant bacteria and environmental dissemination; rapid microbiological diagnosis; and curtailed clinical and veterinary misuse. Fortunately, combating antimicrobial resistance has been highly valued and supported by the government, scientists and entrepreneurs of various countries. With the continuous introduction of new technologies, new products, and new management measures, the problem of antimicrobial resistance must be controlled and alleviated.

High cholesterol is one of the important factors inducing cardiovascular and cerebrovascular diseases. Drug therapy is the main method for reducing cholesterol, but has the disadvantages such as high cost and side effects. Studies have shown that intestinal bacteria play important roles in cholesterol metabolism. However, there are few reports on the screening and functional evaluation of cholesterol-lowering intestinal bacteria. In this study, 36 bile-tolerant bacteria were screened from healthy people stool through culturomics using bovine bile acid or artificial mixed bile acids as substrates. Taking Lactobacillus rhamnosus GG (LGG) as a positive control, three bile acid concentration groups (0 g/L, 0.3 g/L, 3 g/L) were set up to evaluate the cholesterol-lowering ability of bile-tolerant bacteria in vitro. Ten bacteria (including Proteus mirabilis, Providencia stuartii, Proteus vulgaris et al) were identified as the dominant cholesterol-lowering bacteria. Six of the above bacteria, Proteus mirabilis, Providencia stuartii, Proteus vulgaris, Proteus penneri, Wohlfahrtiimonas chitiniclastica, Providencia rettger, were evaluated for their ability to reduce triglycerides in vitro and tolerance to artificial gastric juice. Comparing with strain LGG, the six bacteria showed better triglyceride-lowering ability in vitro. With the decrease of pH value of artificial gastric juice and the increase of treatment time, the survival rate of six bacteria decreased. The above screening experiments and functional evaluation provide a basis for further development of potential cholesterol-lowering bacterial products.
Animals ; Cattle ; Cholesterol ; Gammaproteobacteria ; Humans ; Proteus mirabilis ; Providencia